Verastem to Present at the 30th Annual ROTH Conference

Verastem, Inc. VSTM, focused on developing drugs to improve the survival and quality of life of cancer patients, today announced that the Company will present at the 30^th Annual ROTH Conference on Monday, March 12, 2018 at 4:30 pm PST in Dana Point, CA, USA.

A live webcast of the presentation will be available on the investors section of the Company's website at www.verastem.com. An archived presentation will be available for 90 days.

About Verastem, Inc.

Verastem, Inc. VSTM is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint in the Phase 2 study DYNAMO™ in iNHL and the Phase 3 clinical trial DUO™ in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Verastem has submitted a New Drug Application (NDA) requesting the full approval of duvelisib for the treatment of patients with relapsed or refractory CLL/SLL, and accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma (FL). In addition, Verastem is developing the FAK inhibitor defactinib, which is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer, and mesothelioma. Verastem's product candidates seek to treat cancer by modulating the local tumor microenvironment, enhancing anti-tumor immunity, and reducing cancer stem cells. For more information, please visit www.verastem.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180226005124/en/